Compositions and methods for selective inhibition of pro-angiogenic VEGF isoforms

Details for Australian Patent Application No. 2009322279 (hide)

Owner OPKO Ophthalmics, LLC

Inventors Frost, Phillip; Dejneka, Nadine; Bond, Ottrina S.; Shams, Naveed

Agent Pizzeys

Pub. Number AU-A-2009322279

PCT Pub. Number WO2010/065834

Priority 61/119,779 04.12.08 US; 61/171,571 22.04.09 US; 61/219,808 24.06.09 US

Filing date 4 December 2009

Wipo publication date 10 June 2010

International Classifications

C12N 15/113 (2010.01) Mutation or genetic engineering - Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides

A61K 31/713 (2006.01) - Double-stranded nucleic acids or oligonucleotides

C07H 21/00 (2006.01) Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids

A61P 9/10 (2006.01) Drugs for disorders of the cardiovascular system

A61P 27/02 (2006.01) Drugs for disorders of the senses

A61P 35/00 (2006.01) Antineoplastic agents

Event Publications

14 July 2011 PCT application entered the National Phase

  PCT publication WO2010/065834 Priority application(s): WO2010/065834

25 October 2012 Alteration of Name

  The name of the applicant has been altered to OPKO Pharmaceuticals, LLC 2010

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009322282-Mounting rail and power distribution system for use in a photovoltaic system

2009322274-Hood method and device for material dissection